BEAT earnings

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2026, and will be providing updates on key strategic growth initiatives, including its limited commercial launch for arrhythmia assessment, and developments on its extended-wear patch, heart attack detection and AI initiatives. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answe

HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial Partner ClearCardio™ to Bring HeartBeam's 3D ECG Technology to High-Growth Preventive Cardiology Market First Patients Enrolled in Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Completed the First Working Prototype of an Extended-Wear 12-Lead ECG Patch Strategic Collaboration with the Icahn School of Medicine at Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. ET   HeartBeam, Inc. (NASDAQ:BEAT), a

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2025, and will be providing updates on its key strategic growth initiatives, specifically the limited commercial launch and significant developments on the 12-lead ECG extended wear patch. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. They will

Commercial Readiness Plans Accelerating in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software for Arrhythmia Assessment Anticipated FDA Clearance in Q4 2025 is a Major Inflection Point as HeartBeam Evolves into a Commercial-Stage Company Focused on Growth Announced Partnership with HeartNexus to Provide On-Demand Cardiologist Reviews of Synthesized 12-Lead ECGs for Arrhythmia Assessment and Triage Patients Data Presented at AHA Scientific Sessions and HRX Live 2025 Continue to Advance HeartBeam's Pipeline for Ischemia Detection and Deep Learning Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. E

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, November 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed dur

Executing on Commercial Readiness Plans in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Engaged in Ongoing Productive Discussions with FDA Related to the 510(k) Application Increased Business Development Resources to Match Inbound Interest from Industry Partners Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the second quarter ended June 30, 2025. Second Quarter & Subsequent 2025 Operational Highligh

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Wednesday, August 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during t

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the web

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2024, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be

Continued Clinical and Regulatory Progress on the HeartBeam System Key Appointments to Management Team Completed as Part of Planned Evolution in Preparation for US Commercialization Strengthening Clinical Evidence Base, with Two Additional Studies to be Presented at the American Heart Association Conference in November 2024 Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the third quarter ended September 30, 2024. Third Quarter & Subsequent 2024 Operational Highlights

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, will hold a conference call on Thursday, November 7, 2024 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2024, and will be providing regulatory updates, reviewing ongoing initiatives, and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno, Founder and President Branislav Vajdic, PhD, and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompa

Continued Clinical and Regulatory Progress on the HeartBeam AIMIGo™ System Enrollment Complete in VALID-ECG Clinical Study That Will Be the Basis of the Upcoming FDA Submission on the 12-Lead Synthesis Software Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the second quarter ended June 30, 2024. Second Quarter & Subsequent 2024 Operational Highlights The Company made steady progress toward key clinical and regulatory milestones on its HeartBeam AIMIGo™ System. AIM

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, will hold a conference call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2024, and will be providing regulatory updates, reviewing ongoing initiatives, and anticipated 2024 milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, and Senior Director & Corporate Controller Ravi Malhotra will host the conference call, followed by a question-and-answer period. The conference call will

Continued Clinical and Regulatory Progress on the AIMIGo™ 3D VECG System Presented Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias Management to Host Webcast and Conference Call Today At 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the first quarter ended March 31, 2024. First Quarter & Subsequent 2024 Operational Highlights The Company made steady progress toward key clinical and regulatory milestones on its AIMIGo™ 3D vectorelectrocardiography (3D VECG) system. AIMIGo 510(k) Su

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, will hold a conference call on Thursday May 9, 2024 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024, and will be providing regulatory updates, reviewing ongoing initiatives, and anticipated 2024 milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, and Consulting CFO Richard Brounstein will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a pres

First Patients Enrolled in Pivotal Study Evaluating AIMIGo™ System for Synthesizing a 12-Lead ECG Ongoing Clinical and Regulatory Progress for the AIMIGo 3D VECG System Recently Received 2 New Patents for our Proprietary Technologies Management to Host Webcast and Conference Call Today At 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter & Subsequent 2024 Operational Highlights The company made steady progress toward key clinical and regulator

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, will hold a conference call on Wednesday March 20, 2024 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2023, and will be providing regulatory updates, reviewing ongoing initiatives, and anticipated 2024 milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, Consulting CFO Richard Brounstein, and VP of Regulatory Affairs Deborah Castillo, PhD, will host the conference call, followed by a

Strengthens Leadership with Appointments to Executive Team and Boards Publishes Landmark Peer-Reviewed Article, Validating Technology Ongoing Clinical and Regulatory Progress for the HeartBeam AIMIGo™ VECG Device Management to Host Webcast and Conference Call Today At 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, has reported its financial and operational results for the third quarter ended September 30, 2023. Third Quarter and Subsequent 2023 Operational Highlights Announced the pub

HeartBeam, Inc. (NASDAQ:BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, will hold a conference call on Tuesday November 14, 2023 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2023, and will be reviewing recent announcements, ongoing initiatives, and anticipated 2024 milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno and CFO Richard Brounstein will host the conference call, followed by

HeartBeam, Inc. (NASDAQ:BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, will hold a conference call on Thursday August 10, 2023 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2023, and will be reviewing recent announcements, ongoing initiatives, and key 2023 milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno and CFO Richard Brounstein will host the conference call, followed by a question-and-answer period. The conference call will be accompanie

HeartBeam to Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG Monitoring Platform Funding to Enable Company to Execute on Upcoming Clinical, Regulatory and Commercial Milestones, Extends Cash Runway into Late 2024 HeartBeam to Host Conference Call to Discuss Financing, Strategic Initiatives and First Quarter 2023 Financial Results on Thursday May 11, 2023 at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform to help physicians detect heart attacks anytime, anywhere as well as diagnose other common heart conditions today announced closi

Acquired Assets from LIVMOR, Extending Reach in Remote Monitoring and Detection with an Existing Cutting Edge FDA-Cleared Product, Halo+™ Atrial Fibrillation Detection System Partnered with Evolve Manufacturing to Build HeartBeam AIMIGo 12-Lead 3D Vector Electrocardiogram Device Received European Patent for HeartBeam AIMIGo Technology Initial FDA Submission of HeartBeam AIMIGo™, the Telehealth Solution, Projected for Q2 2023 Management to Host Webcast and Conference Call Today At 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has repo

HeartBeam, Inc. (NASDAQ:BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, will hold a conference call on Thursday March 16, 2023 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2022, and will be reviewing recent announcements, ongoing initiatives, and key 2023 milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will host the conference call, followed by a question-a

 HeartBeam AIMI™ Platform Technology for use in Diagnosing Heart Attacks Submitted to FDA for Clearance Company on Track for Initial FDA Submission of HeartBeam AIMIGo™, the Telehealth Solution, in Q4 2022 AIMIGo Technology Receives Two Additional Patents Company Plans to Broaden Product Portfolio Pipeline with Smartwatch Connectivity Management to Host Webcast and Conference Call Today At 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has reported its financial and operational results for the third quarter ended September 30, 2022.

HeartBeam, Inc. (NASDAQ:BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, will hold a conference call on Thursday November 10, 2022 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2022, and will be reviewing recent announcements, ongoing initiatives, and key 2022 and anticipated 2023 milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO and Founder Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will host the conference call, followed by a question-and-answer period. The conference call wi

Company Remains on Track for FDA Submissions of the HeartBeam AIMI™ Software Platform for the Emergency Department in Q3 2022 & AIMIGo™, the Telehealth Solution, in Q4 2022 Acquires Source Code Access Under the LivMor Partnership Agreement that will be Used to Build a Company-branded Version of the LIVMOR's Halo+ FDA Cleared Turnkey Solution for Remote Patient Monitoring to Connect Physicians and Patients. Management to Host Webcast and Conference Call Today At 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, has reported its financial and operational results for the sec

HeartBeam, Inc. (NASDAQ:BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, will hold a conference call on Thursday August 11, 2022 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2022, and will be reviewing recent announcements, ongoing initiatives and key 2022 milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO and Founder Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, whi

Company Remains on Track for FDA Submission of Emergency Department (ED) Myocardial Infarction (MI) Software Product in Q2 2022 & Telehealth Solution in Q4 2022 Management to Host Webcast and Conference Call Today At 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, has reported its financial and operational results for the first quarter ended March 31, 2022. First Quarter 2022 Operational Highlights Engaged Triple Ring Technologies to co-develop its telehealth complete solution 3D vector ECG collection device for remote heart attack, Myocardial Infarction ("MI"), monit

HeartBeam, Inc. (NASDAQ:BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, will hold a conference call on Thursday May 12, 2022 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2022, and will be reviewing recent announcements, ongoing initiatives and key 2022 milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO and Founder Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which

HeartBeam, Inc. (NASDAQ:BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, will hold a conference call on Thursday, March 24, 2022 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2021, and will be reviewing recent announcements, ongoing initiatives and key 2022 milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO and Founder Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will host the conference call, followed by a question-and-answer period. The conference call will be accompani